(-0.88%) 4 967.23 points
(0.56%) 37 986 points
(-2.05%) 15 282 points
(0.62%) $83.24
(0.17%) $1.760
(0.36%) $2 406.70
(1.29%) $28.75
(-1.17%) $943.30
(-0.14%) $0.938
(-0.28%) $11.01
(0.55%) $0.808
(-0.96%) $93.00
5 days till quarter result
(bmo 2024-04-25)
Expected move: +/- 4.43%
Live Chart Being Loaded With Signals
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection...
Stats | |
---|---|
Today's Volume | 5.53M |
Average Volume | 5.64M |
Market Cap | 294.65B |
EPS | $0 ( 2024-02-02 ) |
Next earnings date | ( $2.34 ) 2024-04-25 |
Last Dividend | $1.550 ( 2024-04-12 ) |
Next Dividend | $0 ( N/A ) |
P/E | 61.18 |
ATR14 | $0.132 (0.08%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-31 | Quaggin Susan E | Buy | 82 | Stock Equivalent Units |
2024-03-31 | Alpern Robert J | Buy | 41 | Stock Equivalent Units |
2024-03-31 | Rapp Edward J | Buy | 212 | Stock Equivalent Units |
2024-03-20 | Donoghoe Nicholas | Sell | 21 082 | Common Stock, $0.01 par value |
2024-03-18 | Stewart Jeffrey Ryan | Buy | 26 110 | Common Stock, $0.01 par value |
INSIDER POWER |
---|
2.47 |
Last 100 transactions |
Buy: 975 676 | Sell: 912 577 |
Volume Correlation
Abbvie Inc Correlation
10 Most Positive Correlations | |
---|---|
YSAC | 0.891 |
MOS | 0.887 |
TDI | 0.882 |
NANR | 0.865 |
BML-PJ | 0.864 |
CHH | 0.864 |
VAL | 0.86 |
TMO | 0.858 |
VLTA | 0.853 |
PACK | 0.847 |
10 Most Negative Correlations | |
---|---|
TGH | -0.863 |
KURE | -0.861 |
PBC | -0.86 |
FRGE | -0.859 |
ALCC | -0.856 |
SID | -0.854 |
CE | -0.847 |
MX | -0.847 |
FDD | -0.844 |
WFC-PD | -0.839 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Abbvie Inc Correlation - Currency/Commodity
Abbvie Inc Financials
Annual | 2023 |
Revenue: | $54.32B |
Gross Profit: | $45.54B (83.84 %) |
EPS: | $2.73 |
Q4 | 2023 |
Revenue: | $14.30B |
Gross Profit: | $11.92B (83.32 %) |
EPS: | $0.460 |
Q3 | 2023 |
Revenue: | $13.93B |
Gross Profit: | $7.44B (53.44 %) |
EPS: | $1.000 |
Q2 | 2023 |
Revenue: | $13.87B |
Gross Profit: | $9.63B (69.42 %) |
EPS: | $1.140 |
Financial Reports:
No articles found.
Abbvie Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$1.410 (N/A) |
$1.410 (N/A) |
$1.480 (N/A) |
$1.480 (N/A) |
$2.96 (N/A) |
$1.480 (N/A) |
$1.550 (N/A) |
$1.550 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.400 | 2013-01-11 |
Last Dividend | $1.550 | 2024-04-12 |
Next Dividend | $0 | N/A |
Payout Date | 2024-05-15 | |
Next Payout Date | N/A | |
# dividends | 47 | -- |
Total Paid Out | $44.05 | -- |
Avg. Dividend % Per Year | 3.70% | -- |
Score | 5.69 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.59 | |
Div. Directional Score | 7.45 | -- |
Year | Amount | Yield |
---|---|---|
2013 | $1.600 | 4.56% |
2014 | $1.660 | 3.19% |
2015 | $2.02 | 3.07% |
2016 | $2.28 | 3.96% |
2017 | $2.56 | 4.10% |
2018 | $3.59 | 3.65% |
2019 | $4.28 | 4.80% |
2020 | $4.72 | 5.27% |
2021 | $5.20 | 4.93% |
2022 | $5.64 | 4.16% |
2023 | $7.40 | 4.56% |
2024 | $3.10 | 1.94% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOMA | Dividend Knight | 2023-06-30 | Quarterly | 2 | 5.23% | 8.53 |
SCM | Dividend King | 2023-12-15 | Monthly | 13 | 7.08% | 8.50 |
SJT | Dividend Royal | 2023-11-29 | Monthly | 39 | 12.52% | 8.50 |
ZTR | Dividend King | 2024-02-09 | Monthly | 37 | 8.35% | 8.50 |
SRV | Dividend Royal | 2023-12-04 | Monthly | 18 | 7.53% | 8.50 |
PHK | Dividend Royal | 2023-11-10 | Monthly | 22 | 6.88% | 8.50 |
JQC | Dividend Royal | 2023-11-14 | Monthly | 22 | 6.56% | 8.50 |
PCF | Dividend King | 2023-12-18 | Monthly | 38 | 7.05% | 8.50 |
GOF | Dividend Royal | 2023-11-14 | Monthly | 18 | 8.03% | 8.50 |
PVL | Dividend Royal | 2023-11-15 | Monthly | 14 | 9.37% | 8.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0895 | 1.500 | 8.21 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0361 | 1.200 | 8.80 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.400 | 1.500 | 6.66 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 2.17 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 0.872 | 0.800 | -0.639 | -0.512 | [1 - 3] |
quickRatioTTM | 0.633 | 0.800 | -0.980 | -0.784 | [0.8 - 2.5] |
cashRatioTTM | 0.339 | 1.500 | 9.23 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.441 | -1.500 | 2.65 | -3.98 | [0 - 0.6] |
interestCoverageTTM | 7.54 | 1.000 | 8.32 | 8.32 | [3 - 30] |
operatingCashFlowPerShareTTM | 12.93 | 2.00 | 5.69 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 12.49 | 2.00 | 3.75 | 7.51 | [0 - 20] |
debtEquityRatioTTM | 5.73 | -1.500 | 10.00 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.685 | 1.000 | 1.913 | 1.913 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.259 | 1.000 | 6.82 | 6.82 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.385 | 1.000 | 8.97 | 8.97 | [0.2 - 2] |
assetTurnoverTTM | 0.403 | 0.800 | -0.645 | -0.516 | [0.5 - 2] |
Total Score | 10.32 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 61.38 | 1.000 | 3.90 | 0 | [1 - 100] |
returnOnEquityTTM | 0.400 | 2.50 | 7.86 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 12.49 | 2.00 | 5.84 | 7.51 | [0 - 30] |
dividendYielPercentageTTM | 3.54 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 12.93 | 2.00 | 5.69 | 10.00 | [0 - 30] |
payoutRatioTTM | 2.17 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | -1.077 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.420 | 1.000 | 1.988 | 0 | [0.1 - 0.5] |
Total Score | 4.59 |
Abbvie Inc
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators